26 January 2016 : Clinical Research
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma
DOI: 10.12659/MSM.896607
Med Sci Monit 2016; 22:276-283
HTML version available soon